South African startup Impulse Biomedical has been accepted into the Maryland Global Gateway Soft Landing Programme, marking its expansion into the US market.
Founded by engineering entrepreneurs Giancarlo Beukes and Gokul Nair, Impulse Biomedical is the force behind breakthrough devices that are reshaping emergency care. Their flagship products include the Easy Squeezy, an affordable and easy-to-use asthma inhaler that empowers patients to manage asthma more effectively, and the ZiBiPen, the world’s first reloadable epinephrine auto-injector.
The startup raised an undisclosed amount of funding from E Squared Investments and ANZA Capital last May, to enable it to commercialise its products, navigate complex regulatory pathways, and expand internationally.
The latter has now been achieved after Impulse Biomedical was accepted into the Maryland Global Gateway Soft Landing Programme, which provides international companies with the support and resources to establish a US presence, including access to facilities, capital, and partner advisors who have appropriate industry knowledge to support the growth of the companies.
“We are truly honoured to be part of the programme as establishing our US presence through the Maryland Global Gateway programme is a pivotal milestone for Impulse Biomedical,” said Beukes. “The strategic support from the Maryland Department of Commerce and the specialised expertise at The LaunchPort will be key in smoothing our transition into the US market, ensuring we are well positioned for long-term success and impact.”
